Senseonics Holdings, Inc. (NYSE:SENS) Receives $22.70 Consensus PT from Analysts

Shares of Senseonics Holdings, Inc. (NYSE:SENS) have been assigned a consensus rating of “Buy” from the six research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $22.70.

SENS has been the subject of a number of recent analyst reports. HC Wainwright increased their price target on shares of Senseonics to $18.50 and gave the company a “buy” rating in a research note on Thursday, November 6th. Barclays reiterated an “overweight” rating and issued a $31.00 target price (up from $1.50) on shares of Senseonics in a research note on Wednesday, November 5th. Stifel Nicolaus began coverage on Senseonics in a research report on Tuesday, October 21st. They set a “hold” rating and a $9.00 price target on the stock. Finally, TD Cowen reaffirmed a “buy” rating on shares of Senseonics in a research report on Thursday, January 8th.

Insider Transactions at Senseonics

In related news, Director Douglas A. Roeder bought 15,000 shares of Senseonics stock in a transaction that occurred on Friday, November 7th. The stock was acquired at an average price of $5.83 per share, with a total value of $87,450.00. Following the acquisition, the director owned 99,727 shares of the company’s stock, valued at approximately $581,408.41. This represents a 17.70% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Frederick T. Sullivan purchased 5,415 shares of the stock in a transaction on Friday, November 7th. The stock was bought at an average cost of $5.88 per share, for a total transaction of $31,840.20. Following the completion of the acquisition, the chief financial officer owned 157,028 shares in the company, valued at approximately $923,324.64. This trade represents a 3.57% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders purchased 30,415 shares of company stock worth $184,790. 3.60% of the stock is owned by insiders.

Institutional Trading of Senseonics

Several institutional investors have recently added to or reduced their stakes in the company. Townsend Asset Management Corp NC ADV bought a new position in Senseonics during the 4th quarter worth $60,000. Jacobs Levy Equity Management Inc. bought a new position in Senseonics during the third quarter worth about $213,000. Ausdal Financial Partners Inc. raised its stake in Senseonics by 50.0% in the 3rd quarter. Ausdal Financial Partners Inc. now owns 105,000 shares of the company’s stock worth $46,000 after purchasing an additional 35,000 shares in the last quarter. Masters Capital Management LLC boosted its holdings in Senseonics by 11.1% in the 3rd quarter. Masters Capital Management LLC now owns 5,000,000 shares of the company’s stock valued at $2,179,000 after purchasing an additional 500,000 shares during the period. Finally, Squarepoint Ops LLC boosted its holdings in Senseonics by 8.4% in the 3rd quarter. Squarepoint Ops LLC now owns 751,916 shares of the company’s stock valued at $328,000 after purchasing an additional 57,951 shares during the period. 12.36% of the stock is currently owned by institutional investors.

Senseonics Stock Performance

SENS opened at $6.82 on Friday. The business’s 50-day simple moving average is $6.50 and its 200 day simple moving average is $8.01. Senseonics has a 52-week low of $5.25 and a 52-week high of $28.00. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The firm has a market capitalization of $278.66 million, a PE ratio of -52.46 and a beta of 0.63.

Senseonics Company Profile

Senseonics Holdings, Inc is a medical technology company focused on the development and commercialization of innovative continuous glucose monitoring (CGM) systems for people with diabetes. Since its founding in 2011 and headquartered in Germantown, Maryland, the company has pioneered an implantable sensor designed to deliver long-term glucose readings. Senseonics’ mission centers on improving diabetes management by providing accurate, real-time data to patients and healthcare providers.

The company’s flagship offering is the Eversense CGM System, which features a small, fully implantable sensor placed beneath the skin to measure glucose levels for up to 90 days in the United States and up to 180 days in Europe.